Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
August 10 2022 - 4:01PM
Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global
biopharmaceutical company dedicated to the discovery, development,
and commercialization of novel therapies for the treatment of
cancer and related conditions, today announced that it intends to
offer and sell, subject to market conditions, shares of its common
stock, or pre-funded warrants to purchase common stock in lieu of
common stock to certain investors, and accompanying warrants to
purchase shares of its common stock, in an underwritten public
offering. All of the shares of common stock, warrants and
pre-funded warrants are being offered by Athenex.
SVB Securities is acting as sole
book-running manager for the offering. The offering is subject to
market conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
The offering is being made only by means of a
previously filed effective registration statement (including a base
prospectus) and a preliminary prospectus supplement. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to this offering, when available, may be obtained
from: SVB Securities LLC, Attention: Syndicate Department, 53
State Street, 40th Floor, Boston, MA 02109, or by telephone at
(800) 808-7525, ext. 6105, or by email at
syndicate@svbsecurities.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there by any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Athenex,
Inc. Founded in 2003, Athenex, Inc. is a
global clinical-stage biopharmaceutical company dedicated to
becoming a leader in the discovery, development, and
commercialization of next generation cell therapy drugs for the
treatment of cancer. In pursuit of this mission,
Athenex leverages years of experience in research and
development, clinical trials, regulatory standards, and
manufacturing. The Company’s current clinical pipeline is derived
mainly from the following core technologies: (1) Cell therapy,
based on NKT cells and (2) Orascovery, based on a P-glycoprotein
inhibitor. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active, accessible,
and tolerable treatments.
Forward Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. These forward-looking
statements are typically identified by terms such as “anticipate,”
“continue,” “could,” “expect,” “intend,” “may,” “plan,”
“potential,” “strategy” “will,” and similar expressions. While
Athenex believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Athenex’s filings with the SEC), many of which are beyond
Athenex’s control and subject to change. Actual results might
differ materially from those explicit or implicit in the
forward-looking statements. Risks and uncertainties include:
changes as a result of market conditions or for other reasons; the
risk that the offering will not be consummated; the exercise of the
warrants to be issued in the offering; the impact of general
economic, health, industrial or political conditions in the United
States or internationally; and other risks and uncertainties
identified in Athenex’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2022 and other subsequent disclosure
documents filed with the SEC. All information provided in this
release is as of the date hereof, and we assume no obligation and
do not intend to update these forward-looking statements, except as
required by law.
ContactsDaniel Lang, MDAthenex,
Inc.Email: danlang@athenex.com
Caileigh DoughertyAthenex,
Inc.Email: cdougherty@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024